IFRX
InflaRx NV
NASDAQ · Healthcare · Biotechnology · DE
$1.37
−15.74%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.61
From 52W high−50.18%
Volume1.24M
Market cap$201.16M
P/E (TTM)—
P/S (TTM)−5297.6x
Div yield—
Key dataNov 4, 2026
Open
$1.61
From 52W high
−50.18%
Volume
1.24M
Market cap
$201.16M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.3x
P/E (TTM)
—
RSI (14)
36.3
MomentumView details →
1D Return
−15.74%
YTD Return
+37.21%
SummaryUpdated Sep 1, 2026
InflaRx N.V. (NASDAQ:IFRX) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Jena, Germany. Originally established as Fireman B.V., the company rebranded to InflaRx in 2017, the same year it went public on NASDAQ. The company specializes in discovering and developing novel therapeutics that target the complement system, specifically focusing on C5a inhibition technology to treat autoimmune and inflammatory diseases. InflaRx operates primarily in Germany and the United States, developing treatments for rare and debilitating conditions where significant unmet medical needs exist.
Similar companies
Latest newsMore news →
InflaRx N.V. announced an advisory board of international experts in vasculitis, nephrology and immune-mediated renal disease.1d agoInflaRx N.V. said it plans to initiate a pilot study of izicopan in IgA nephropathy in 2027, with early data expected in 2028.1d agoInflaRx N.V. announced plans to begin two Phase 2 izicopan trials in ANCA-associated vasculitis in 2027, with initial data expected in 2028.1d ago